Interleukine-2 ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 61 | Autoimmune hemolytic anemia | 1 |
61. Autoimmune hemolytic anemia
Clinical trials : 137 / Drugs : 127 - (DrugBank : 55) / Drug target genes : 26 - Drug target pathways : 153
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02389231 (ClinicalTrials.gov) | May 17, 2017 | 13/2/2015 | Evaluating the Interest of Interleukine-2 for Patients With Active Warm Hemolytic Anemia Resistant to Conventional Treatment | Anemil Trial : Phase I/II Clinical Trial Evaluating the Interest of Interleukine-2 for Patients With Active Warm Hemolytic Anemia Resistant to Conventional Treatment | Autoimmune Hemolytic Anemia | Drug: Interleukine-2 | University Hospital, Bordeaux | NULL | Completed | 18 Years | N/A | All | 2 | Phase 1/Phase 2 | France |